• About Us
  • Technology
  • Pipeline
  • Media
  • Careers
  • Contact Us
Churchill Logo
  • About Us
  • Technology
  • Pipeline
  • Media
  • Careers
  • Contact Us

Media

  • News
  • Press Releases

Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study

November 22, 2017


The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers

November 16, 2017


Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...

July 20, 2017


Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Click here to view the article.

July 10, 2017


Churchill Pharmaceuticals launches a new updated website with a fresh design

King of Prussia, PA., May 16, 2017 Churchill Pharmaceuticals, a drug development biopharmaceutical company specialized in oral oncology, announced the...

May 22, 2017


Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects, Clinical Pharmacokinetics 2017

Click here to view the article.

May 5, 2017


About Us

The Churchill team pairs depth-of-experience with an agile, entrepreneurial approach to responsibly bring forward improved oral oncology products

LEARN MORE
  • About Us
  • Compliance
  • Technology
  • Pipeline
  • Media
  • News
  • Press Releases

Careers at
Churchill Pharmaceuticals

Working together, we can unleash agility and insight to responsibly expand oral oncology treatment options for physicians and patients.

VIEW OPEN POSITIONS

Churchill Logo
  • Connect with us
  • Terms of Use
  • Privacy Policy
  • Site Map
  • Contact Us

©2023 Churchill Pharmaceuticals LLC. All rights reserved.

You're are now leaving Churchillpharma.com

You are leaving the Churchill Pharmaceuticals website. This link will take you to a website to which our Privacy Policy does not apply. Churchill Pharmaceuticals does not control the content of this third-party site.

Continue Cancel